Fmoc-D-Ala(cBu)-OH
Need Assistance?
  • US & Canada:
    +
  • UK: +

Fmoc-D-Ala(cBu)-OH

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
Fmoc-Amino Acids
Catalog number
BAT-008778
CAS number
478183-63-0
Molecular Formula
C22H23NO4
Molecular Weight
365.4
Fmoc-D-Ala(cBu)-OH
IUPAC Name
(2R)-3-cyclobutyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
Synonyms
Fmoc-D-Ala(β-cyclobutyl)-OH; Fmoc-β-cyclobutyl-D-Ala-OH; Fmoc-beta-cyclobutyl-D-Ala-OH; Fmoc-D-Ala(b-cyclobutyl)-OH
Purity
95%
InChI
InChI=1S/C22H23NO4/c24-21(25)20(12-14-6-5-7-14)23-22(26)27-13-19-17-10-3-1-8-15(17)16-9-2-4-11-18(16)19/h1-4,8-11,14,19-20H,5-7,12-13H2,(H,23,26)(H,24,25)/t20-/m1/s1
InChI Key
FOJRBUNCWCPLNH-HXUWFJFHSA-N
Canonical SMILES
C1CC(C1)CC(C(=O)O)NC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24

Fmoc-D-Ala(cBu)-OH, a derivative of the amino acid D-alanine shielded by an Fmoc group and substituent, finds diverse applications across various fields. Here are the key applications, highlighted with elevated perplexity and burstiness:

Peptide Synthesis: At the forefront of solid-phase peptide synthesis, Fmoc-D-Ala(cBu)-OH serves as a fundamental building block for protected D-alanine. Its Fmoc group enables selective deprotection, facilitating the meticulous addition of amino acids to the growing peptide chain. This meticulous process ensures the synthesis of peptides boasting high purity, specific sequences, and intricate structural configurations.

Pharmaceutical Development: In the realm of drug design, Fmoc-D-Ala(cBu)-OH plays a pivotal role in crafting peptide-based therapeutics. By incorporating D-amino acids like D-alanine, researchers enhance the stability and bioavailability of pharmaceutical peptides. This compound is instrumental in improving drug efficacy and curbing metabolic degradation, revolutionizing the landscape of pharmaceutical innovation.

Structural Biology: Employed in creating peptide substrates and inhibitors for enzyme studies, Fmoc-D-Ala(cBu)-OH elevates the field of structural biology. The introduction of D-alanine confers resistance to proteolytic cleavage in peptides, enabling precise exploration of enzyme activity and substrate interactions. This detailed analysis sheds light on enzyme mechanisms, unveiling potential drug targets and paving the way for groundbreaking advancements in pharmaceutical research.

Materials Science: In the realm of materials science, Fmoc-D-Ala(cBu)-OH emerges as a pivotal component in developing cutting-edge biomaterials and hydrogels. By integrating this compound into peptide sequences, scientists can design materials with tailored mechanical properties and biological functionalities. These advanced materials find applications in diverse fields such as tissue engineering, drug delivery, and regenerative medicine, fostering innovation and progress in material science.

1. Comproportionation reactions to manganese(III/IV) pivalate clusters: a new half-integer spin single-molecule magnet
Shreya Mukherjee, Khalil A Abboud, Wolfgang Wernsdorfer, George Christou Inorg Chem. 2013 Jan 18;52(2):873-84. doi: 10.1021/ic302021a. Epub 2012 Dec 28.
The comproportionation reaction between Mn(II) and Mn(VII) reagents under acidic conditions has been investigated in the presence of pivalic acid as a route to new high oxidation state manganese pivalate clusters containing some Mn(IV). The reaction of Mn(O(2)CBu(t))(2) and NBu(n)(4)MnO(4) with an excess of pivalic acid in the presence of Mn(ClO(4))(2) and NBu(n)(4)Cl in hot MeCN led to the isolation of [Mn(8)O(6)(OH)(O(2)CBu(t))(9)Cl(3)(Bu(t)CO(2)H)(0.5)(MeCN)(0.5)] (1). In contrast, the reaction of Mn(NO(3))(2) and NBu(n)(4)MnO(4) in hot MeCN with an excess of pivalic acid gave a different octanuclear complex, [Mn(8)O(9)(O(2)CBu(t))(12)] (2). The latter reaction but with Mn(O(2)CBu(t))(2) in place of Mn(NO(3))(2), and in a MeCN/THF solvent medium, gave [Mn(9)O(7)(O(2)CBu(t))(13)(THF)(2)] (3). Complexes 1-3 possess rare or unprecedented Mn(x) topologies: 1 possesses a [Mn(III)(7)Mn(IV)(μ(3)-O)(4)(μ(4)-O)(2)(μ(3)-OH)(μ(4)-Cl)(μ(2)-Cl)](8+) core consisting of two body-fused Mn(4) butterfly units attached to the remaining Mn atoms via bridging O(2-), OH(-), and Cl(-) ions. In contrast, 2 possesses a [Mn(6)(IV)Mn(2)(III)(μ(3)-O)(6)(μ-O)(3)](12+) core consisting of two [Mn(3)O(4)] incomplete cubanes linked by their O(2-) ions to two Mn(III) atoms. The cores of 1 and 2 are unprecedented in Mn chemistry. The [Mn(III)(9)(μ(3)-O)(7)](13+) core of 3 also contains two body-fused Mn(4) butterfly units, but they are linked to the remaining Mn atoms in a different manner than in 1. Solid-state direct current (dc) and/or alternating current (ac) magnetic susceptibility data established S = (15)/(2), S = 2, and S = 1 ground states for 1·MeCN, 2·(1)/(4)MeCN, and 3, respectively. The ac susceptibility data also revealed nonzero, frequency-dependent out-of-phase (χ″(M)) signals for 1·MeCN at temperatures below 3 K, suggesting possible single-molecule magnet behavior, which was confirmed by single-crystal magnetization vs dc field scans that exhibited hysteresis loops. The combined work thus demonstrates the continuing potential of comproportionation reactions for isolating high oxidation state Mn(x) clusters, and the sensitivity of the product identity to minor changes in the reaction conditions.
2. Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?
Mouhamed Yazan Abou-Ismail, et al. Br J Haematol. 2022 May;197(3):326-338. doi: 10.1111/bjh.18108. Epub 2022 Mar 14.
It is not known whether obesity has a differential effect on allogeneic haematopoietic cell transplantation outcomes with alternative donor types. We report the results of a retrospective registry study examining the effect of obesity [body mass index (BMI) > 30] on outcomes with alternative donors (haploidentical related donor with two or more mismatches and receiving post-transplant cyclophosphamide [haplo] and cord blood (CBU)] versus matched unrelated donor (MUD). Adult patients receiving haematopoietic cell transplantation for haematologic malignancy (2013-2017) (N = 16 182) using MUD (n = 11 801), haplo (n = 2894) and CBU (n = 1487) were included. The primary outcome was non-relapse mortality (NRM). The analysis demonstrated a significant, non-linear interaction between pretransplant BMI and the three donor groups for NRM: NRM risk was significantly higher with CBU compared to haplo at BMI 25-30 [hazard ratio (HR) 1.66-1.71, p < 0.05] and MUD transplants at a BMI of 25-45 (HR, 1.61-3.47, p < 0.05). The results demonstrated that NRM and survival outcomes are worse in overweight and obese transplant recipients (BMI ≥ 25) with one alternative donor type over MUD, although obesity does not appear to confer a uniform differential mortality risk with one donor type over the other. BMI may serve as a criterion for selecting a donor among the three (MUD, haplo and CBU) options, if matched sibling donor is not available.
Online Inquiry
Verification code
Inquiry Basket